Neurotech International Limited (ASX:NTI)

5.6¢

right-arrow Created with Sketch. -0.007 (-11.11%)
MCAP $39.04M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

18/11/2021NTINeurotech International Limited
16/11/2021NTINeurotech International Limited
08/11/2021NTINeurotech International Limited
29/10/2021 Price SensitivePSNTINeurotech International Limited
25/10/2021NTINeurotech International Limited
25/10/2021NTINeurotech International Limited
22/10/2021NTINeurotech International Limited
19/10/2021NTINeurotech International Limited

Company Overview

Neurotech International Limited is an Australia-based medical device and solutions company. The Company operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The Company is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The Company through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.

NTI in the news

Neurotech (NTI) is set to pocket $3.5 million via an underwritten exercise…
Neurotech International (NTI) has tumbled on the ASX today after releasing the…
Shares in healthcare stock Neurotech International (NTI) will stay grey until mid…
Neurotech International (NTI) has received promising early results from testing on the…

Search Previous Announcements